 Home > Medical News > Latest Medical News > AstraZeneca Olapali successfully first-line treatment of prostate cancer in Phase III clinical trial

AstraZeneca Olapali successfully first-line treatment of prostate cancer in Phase III clinical trial

 Last Update: 2021-10-11
 Source: Internet
 Author: User

Tags

time release morphine

aggressive prostate cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 24, AstraZeneca announced that olaparza (Lynparza) combined with abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) phase III clinical PROpel study reached rPFS (radiological progress in the interim analysis) Survival) the primary endpoint, showing a statistically significant and clinically significant improvement, regardless of the patient's homologous recombination repair (HRR) mutation status

At the same time, the trial also showed an improvement in overall survival (OS) in the interim analysis

PROpel is a randomized, double-blind, multicenter phase III trial that evaluated the efficacy and safety of Lynparza combined with abiraterone and placebo combined with abiraterone in a first-line setting

Prostate cancer is the second most common cancer in men

In 2014, olaparib was approved by the FDA for the first time for marketing in patients with advanced ovarian cancer with BRCA mutations

Since its approval, its sales have been growing.

In China, the drug has also been approved for multiple indications

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.